ATAI Life Sciences NV
9VC
Company Profile
Business description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Contact
Wallstrasse 16
BerlinBB10179
DEUT: +49 8921539035
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
54
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,571.40 | 40.30 | -0.47% |
| CAC 40 | 7,864.44 | 46.05 | -0.58% |
| DAX 40 | 23,999.17 | 123.23 | -0.51% |
| Dow JONES (US) | 41,859.09 | 1.35 | -0.00% |
| FTSE 100 | 8,739.26 | 47.20 | -0.54% |
| HKSE | 23,544.31 | 283.47 | -1.19% |
| NASDAQ | 18,925.73 | 53.09 | 0.28% |
| Nikkei 225 | 36,985.87 | 313.11 | -0.84% |
| NZX 50 Index | 12,662.25 | 40.85 | -0.32% |
| S&P 500 | 5,842.01 | 2.60 | -0.04% |
| S&P/ASX 200 | 8,348.70 | 38.10 | -0.45% |
| SSE Composite Index | 3,380.19 | 7.39 | -0.22% |